GLP-3 vs GLP-2: Research Comparison
GLP-3 and GLP-2 are the research designations used by J.Pharma for two distinct metabolic peptide compounds with overlapping but meaningfully different receptor profiles. Understanding the mechanistic differences is important for designing research protocols that target specific incretin pathways.
Quick Reference Comparison
| Property | GLP-3 | GLP-2 |
|---|---|---|
| Receptor targets | GIP + GLP-1 + Glucagon | GIP + GLP-1 |
| Receptor count | Triple agonist | Dual agonist |
| Glucagon pathway | Yes | No |
| Available sizes | 10mg, 20mg, 30mg, 60mg | 10mg, 20mg |
| Starting price | $75 | $60 |
| Reconstitution | 1mL BAC/10mg (10mg/mL) | 1mL BAC/10mg (10mg/mL) |
| Special handling | Standard | Prone to foaming |
Receptor Profiles in Detail
GIP receptor (shared by both): The glucose-dependent insulinotropic polypeptide receptor is activated by both compounds. GIP receptor activation influences insulin secretion in a glucose-dependent manner and may modulate adipose tissue metabolism and energy balance through mechanisms that remain an area of active research.
GLP-1 receptor (shared by both): Glucagon-like peptide-1 receptor activation is a well-studied pathway. It reduces gastric emptying rate, suppresses glucagon secretion, and decreases appetite signaling through both central (hypothalamic) and peripheral mechanisms. This is the primary receptor targeted by older generation single-agonist compounds.
Glucagon receptor (GLP-3 only): This is the key mechanistic distinction. Glucagon receptor activation promotes hepatic glucose output and increases energy expenditure through thermogenic mechanisms. Research interest in adding glucagon agonism to GIP/GLP-1 dual agonism centers on whether the additional energy expenditure component produces meaningfully different metabolic outcomes in research models.
Research Use Cases
Use GLP-2 when: Your research is focused specifically on dual incretin pathway (GIP + GLP-1) effects, or you are conducting comparative studies against GLP-1 monoagonists. GLP-2 is also the more appropriate choice when you want to study GIP contribution to GLP-1 outcomes without the confounding variable of glucagon pathway activity.
Use GLP-3 when: Your research investigates triple-receptor agonism, the specific contribution of glucagon receptor activation to metabolic outcomes, or comparative studies between dual and triple receptor agonist mechanisms. The 30mg and 60mg formats make GLP-3 more practical for extended research protocols.
Use both when: Comparative research specifically designed to isolate the contribution of the glucagon receptor component — using GLP-2 as a dual agonist control and GLP-3 as the triple agonist experimental condition.
Handling Differences
The two compounds have one notable handling difference: GLP-2 is particularly prone to foaming during reconstitution. Add BAC Water very slowly, angled down the vial wall. If foaming occurs, allow the vial to rest in the refrigerator for 10-15 minutes before use — do not try to swirl out the foam. GLP-3 reconstitutes without this foaming tendency under standard protocol.
Both compounds produce clear, colorless solutions and have identical storage requirements: refrigerate at 2-8°C after reconstitution, stable 28-42 days.